enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Why VIVUS Lost in November - AOL

   www.aol.com/news/2012-12-04-why-vivus-lost-in...

   VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...

3. VIVUS Obesity Drug Sales Only About 60% of Expectations - AOL

   www.aol.com/news/2013-02-25-vivus-obesity-drug...

   VIVUS has traded in a 52-week trading range of $9.86 to $31.21, and the consensus analyst price target from Thomson Reuters was $19.59 before the effects of today's earnings.

4. Does The VIVUS, Inc. (NASDAQ:VVUS) Share Price Fall ... - AOL

   www.aol.com/news/does-vivus-inc-nasdaq-vvus...

   For premium support please call: 800-290-4726 more ways to reach us

5. VVUS: New Ideas for Established Portfolio

   www.aol.com/news/vvus-ideas-established...

   We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...

6. Is a VIVUS Buyout Still on the Table? And if So, by Whom? - AOL

   www.aol.com/news/2012-10-12-is-a-vivus-buyout...

   For premium support please call: 800-290-4726 more ways to reach us

7. Buy, Sell, or Hold: VIVUS

   www.aol.com/2012/06/12/buy-sell-or-hold-vivus

   For premium support please call: 800-290-4726 more ways to reach us

8. Can This Forgotten Drug Save VIVUS Investors? - AOL

   www.aol.com/news/2012-11-06-can-this-forgotten...

   The three main players in the obesity drug space -- VIVUS (NAS: VVUS) , Arena Pharmaceuticals (NAS: ARNA) , and Orexigen Therapeutics (NAS: OREX) -- are prepared to brave the market's reaction and ...

9. Why VIVUS Shares Soared - AOL

   www.aol.com/news/2012-10-08-why-vivus-shares...

   For premium support please call: 800-290-4726 more ways to reach us